# A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients with Advanced or Metastatic Solid Tumors

> **NCT05983523** · PHASE1 · RECRUITING · sponsor: **PharmaEngine** · enrollment: 54 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Metastatic Solid Tumor

## Interventions

- **DRUG:** PEP07

## Key facts

- **NCT ID:** NCT05983523
- **Lead sponsor:** PharmaEngine
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-27
- **Primary completion:** 2027-02-25
- **Final completion:** 2027-08-31
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2024-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05983523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05983523, "A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients with Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05983523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*